Affordable Access

deepdyve-link
Publisher Website

Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study.

Authors
  • van Lee, C B1
  • Roorda, B M2
  • Wakkee, M1
  • Voorham, Q3
  • Mooyaart, A L4
  • de Vijlder, H C5
  • Nijsten, T1
  • van den Bos, R R1
  • 1 Department of Dermatology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands. , (Netherlands)
  • 2 Department of Dermatology, University Medical Centre Groningen, Groningen, the Netherlands. , (Netherlands)
  • 3 PALGA: The Nationwide Network and Registry of Histology and Cytopathology, Houten, the Netherlands. , (Netherlands)
  • 4 Department of Pathology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands. , (Netherlands)
  • 5 Department of Dermatology, Isala Hospital, Zwolle, the Netherlands. , (Netherlands)
Type
Published Article
Journal
British Journal of Dermatology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Aug 01, 2019
Volume
181
Issue
2
Pages
338–343
Identifiers
DOI: 10.1111/bjd.17188
PMID: 30199574
Source
Medline
Language
English
License
Unknown

Abstract

Recurrent cutaneous squamous cell carcinoma (cSCC) has been associated with an increased risk of local functional and aesthetic comorbidity, metastasis and mortality. To compare the risk of recurrence between Mohs micrographic surgery (MMS) and standard excision for cSCC of the head and neck. This was a retrospective cohort study of all patients with a cSCC treated with MMS or standard excision at the departments of dermatology of a secondary or tertiary care hospital in the Netherlands between 2003 and 2012. To detect all recurrences, patients were linked to the Dutch pathology registry. To compare the risk of recurrence between MMS and standard excision, hazard ratios (HRs) were used adjusted for clinical tumour size > 2 cm and deep tumour invasion. A total of 579 patients with 672 cSCCs were included: 380 cSCCs were treated with MMS and 292 with standard excision. The risk of recurrence was 8% (22 of 292) after standard excision during a median follow-up of 5·7 years [interquartile range (IQR) 3·5-7·8], which was higher than the 3% (12 of 380) after MMS during a median follow-up of 4·9 years (IQR 2·3-6·0). The cumulative incidence of recurrence was higher for standard excision than for MMS during the entire follow-up period of 8·6 years. Carcinomas treated with MMS were at a three times lower risk of recurrence than those treated with standard excision when adjusted for tumour size and deep tumour invasion (adjusted HR 0·31, 95% confidence interval 0·12-0·66). MMS might be superior to standard excision for cSCCs of the head and neck because of a lower rate of recurrence. © 2018 British Association of Dermatologists.

Report this publication

Statistics

Seen <100 times